Icaritin acts synergistically with epirubicin to suppress bladder cancer growth through inhibition of autophagy

Introduction

Bladder cancer, second to prostate cancer, is a commonly diagnosed cancer of the genito-urinary system. According to 2014 cancer statistics of the American Cancer Society (ACS), 141,610 new cases of bladder cancer and 30,350 cancer-related deaths were estimated in the USA in the genito-urinary system (1). The most common type of bladder cancer tissue is transitional cell carcinoma, which accounts for more than 90% of all bladder carcinoma cases (2). Additionally, ~70% transitional cell carcinomas are superficial tumors. Transurethral resection (TUR) is the primary regimen for patients with superficial bladder tumors (stages Ta, T1 or Tis) (3). However, the recurrence rate within 5 years after TUR is as high as 50–70% (4), and 10–20% of them progressed to muscle-invasive disease (5). The anthracycline epirubicin (EPI) is the first line treatment routinely used in patients with bladder cancer after TUR (6). Although prophylactic EPI can effectively reduce the recurrence rate of bladder cancer after TUR, the acquired drug resistance still remains a serious issue in bladder cancer patients.

Icaritin (Fig. 1A) is a hydrolytic form of icariin which is one of the traditional Chinese herbals (7). Icaritin has been shown to have a wide range of pharmacological and biological activities, including stimulating neuronal differentiation via estrogen-dependent pathway (8,9), promoting differentiation of embryonic stem cells into cardiomyocytes (10,11), inhibiting osteoclast differentiation (12) and promoting apoptosis and suppressing proliferation of prostatic smooth muscle cells (13). In addition, numerous studies have demonstrated that icaritin effectively promoted apoptosis, inhibited cell proliferation and induced cell cycle arrest in breast, endometrial and prostate cancer, and renal cancer cells (14–18). Icaritin is expected to work as an effective antitumor agent to regulate cancer cell growth via various pathways. However, the function of icaritin against bladder cancer has not been studied yet.

Figure 1 Icaritin time- and dose-dependently inhibits the proliferation of BT5637 and T24 cells. (A) The chemical structure of icaritin. (B–G) A total of 6×103 cells/well of BT5637 cells, 6×103 cells/well of 293 cells, and 4×103 cells/well of T24 cells were seeded into 96-well plates and incubated with DMSO vehicle control or varying concentrations of icaritin for 24, 48 and 72 h. Proliferation of cells was evaluated using MTT assay. (B and C) Effects of icaritin on the proliferation of BT5637 cells. (D and F) Effects of icaritin on the proliferation of T24 cells. (E and G) Effects of icaritin on the proliferation of 293 cells. Data are expressed as mean ± SD, *P<0.05, **P<0.01, ***P<0.001 vs. DMSO vehicle control.

Autophagy has dual roles in cancer, acting as a tumor suppressor and as a mechanism of cell survival that can promote the growth of established tumors (19). In normal cells, a well regulated autophagy may prevent the accumulation of damaged proteins and organelles to protect cells from apoptosis or tumorigenesis. However, in tumor cells, autophagy will convey a pro-survival signal to adapt tumor cells to various adverse conditions, such as starvation and chemotoxicity. Autophagy is upregulated upon interferon-α (IFN-α) treatment to induce IFN-α resistance in bladder cancer cells (20). In addition, autophagy protects breast cancer cells from EPI-induced apoptosis and facilitates epirubicin-resistance development (21). The p53-induced glycolysis and apoptosis regulator (TIGAR) inhibits autophagy, resulting in reduced sensitivity of cancer cells to epirubicin treatment (22). Several studies have reported that apoptosis of cancer cells is markedly enhanced by pharmacological or genetic mediated inhibition of autophagy (23–25). Furthermore, autophagy inhibitors such as 3-methyladenine or inhibition of autophagy regulatory pathways have been proved to sensitize cancer cells to chemotherapeutic agents (20–22).

The primary objective of the present investigation was to explore the antitumor molecular mechanism of icaritin in the treatment of human bladder cancer cells. To better understand the function of icaritin in treating bladder cancer, we studied the effects of icaritin on proliferation, apoptosis and autophagy of human bladder cancer BT5637 and T24 cells, and explored the sensitivity of cancer cells to EPI treatment.

Materials and methods

Reagents and antibodies

Icaritin (purity 98%; Shanghai Yuanye Biotechnology Co., Ltd., China) was dissolved in dimethylsulfoxide (DMSO) solution to reach a concentration of 50 mM, and then stored at −20°C before use. The stock solution was diluted to the final concentration using correspondent cell culture medium, and the final DMSO concentration in experimental culture medium was <0.1%. Therefore, 0.1% DMSO was used as control vehicle throughout the present study. Epirubicin was purchased from AdooQ BioScience (10 mg). The antibodies of ATG3 (#3415), ATG5 (#8540), ATG7 (#2631) and LC3B (#3868) were purchased from Cell Signaling Technology. GAPDH was purchased from ProteinTech Group (10494-1-AP).

Cell culture

The bladder cancer cell line BT5637 and T24 and the normal renal cell line HEK293 were purchased from the Cell Bank of Chinese Academy of Science. BT5637 cells were cultured in RPMI-1640 culture medium (Hyclone) with 10% fetal bovine serum (FBS), 1% non-essential amino acid (100X) and 2 g/l glucose. T24 cells were cultured in McCoys' 5A culture medium (Sigma) with 10% FBS. HEK293 cells were cultured in DMEM culture medium (HyClone) with 10% FBS and 2 mmol/l glutamine. All these cells were cultured in a humidified atmosphere of 95% air and 5% CO2 at 37°C.

Cell proliferation assay

The 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay was carried out to evaluate the viability and proliferation of cells. A total of 6×103 cells/well for BT5637 and HEK293 cells and 4×103 cells/well for T24 cells were, respectively, seeded into a 96-well plate, and incubated in respective culture medium for 24 h at 37°C. Then culture medium was replaced with fresh culture medium containing varying concentrations of icaritin, and these cells were incubated for 24, 48 and 72 h. At each time point, cells of each well were added with 20 µl of 5 mg/ml MTT solution (Sigma). After 6-h incubation at 37°C, the formazan crystals were dissolved by adding 100 µl DMSO into each well. The absorbance rate was measured at 570 nm using a spectrophotometer (Epoch Synergy 2; BioTek, USA). Each experiment was carried out in triplicates.

Colony formation assay

BT5637 and T24 cells were plated into 6-well plates (6×102 cells/well) in triplicate and were incubated for 24 h at 37°C. The culture medium was then removed and fresh culture medium containing varying concentrations of icaritin was added into each well. After 48-h incubation at 37°C, the special culture medium was changed to culture medium without icaritin. Cell culture was terminated when most colonies contained >50 cells. Subsequently, cells were washed twice with phosphate-buffered saline (PBS), fixed in 1 ml paraformaldehyde for 30 min, stained with 500 µl Giemsa dye for 20 min and washed again with ddH2O. Individual colonies were photographed using a microscope, the plates were photographed using a digital camera, and the colonies with >50 cells were counted. Each experiment was repeated three times.

Measurement of mitochondrial membrane potential (MMP)

JC-1 (Beyotime) staining assay as previously described (26) was carried out to measure MMP. A total of 2×104 cells/well BT5637 or T24 cells were seeded into a 6 cm plate in triplicate and cultured at 37°C. After 24-h incubation, the culture medium was changed to fresh culture medium containing varying concentrations of icaritin and then cells were incubated for 72 h at 37°C. At the designated time point, cells were trypsinized, resuspended, incubated with special culture medium containing JC-1 staining solution for 30 min at 37°C, stained, washed twice using staining buffer and resuspended with 500 µl staining buffer. Healthy cells with high-MMP in the form of JC-1 aggregates showed red fluorescence, and apoptotic cells with low-MMP in the form of JC-1 monomer emitted green fluorescence only. Finally, the stained cells were analyzed using flow cytometry (BD Biosciences).

Western blotting

The T24 and BT5637 cells were previously treated with five concentrations of icaritin for 24, 48 and 72 h, respectively. Proteins were extracted in lysis buffer. Following quantification by ultraviolet spectrophotometry, ~30–60 µg total proteins in each lane were separated by SDS-PAGE (10 and 12% gels), and electrophoretically transferred onto nitrocellulose membranes. The membranes were blocked for 1 h in 5% non-fat milk in TBS/T and then incubated with various autophagy antibodies in 3% non-fat milk at 4°C overnight (1:500; Cell Signaling Technology). The next day, the membranes were washed three times for 10 min, incubated in secondary antibody of anti-rabbit HRP (1:10,000), washed again three times for 10 min, and finally exposed to enhanced chemiluminescence (ECL) detection reagents (Amersham Pharmacia Biotech), and photographed.

Synergistic effect

The synergistic effect of drug combinations was evaluated by Chou-Talalay combination index (CI) equation as follows: CI = Da/(Dx)a + Db/(Dx)b (27), where Da, (Dx)a, Db and (Dx)b indicate the IC50 value of drug A and B combination, drug A alone, drug B and A combination and drug B alone, respectively. CI value of <1, 1, or >1 indicate a synergic, additive, or antagonistic effect of two drugs, respectively.

Statistical analysis

The SPSS 19.0 (SPSS, Inc.) was used to carry out statistical analyses. The data are shown as mean ± SD. Statistically significant differences between groups were analyzed using Student's t-test and P<0.05 was considered to indicate a statistical significant result.

Results

Icaritin time- and dose-dependently inhibits proliferation of bladder cancer cells

To explore the effect of icaritin in bladder cancer cells, a dose-time-effect study was performed in BT5637 and T24 cells treated with concentration gradient of icaritin (2.5, 5, 10, 20 and 50 µM) for 24, 48 and 72 h. As shown in Fig. 1B–F, icaritin inhibited the proliferation of both BT5637 and T24 cells dose- and time-dependently, as compared with DMSO vehicle control.

To verify the specificity of icaritin on bladder cancer cells rather than on normal human cells, we explored the IC50 of icaritin on normal human HEK293 cells. As shown in Fig. 1F and G, cell proliferation was minimally suppressed in 293 cells after icaritin treatment for 24 and 48 h. The IC50 of icaritin on 293 cells at 72 h was 126.58 µM. Whereas, the IC50 of icaritin was 11.6, 7.21 and 4.46 µM on BT5637 cells; 36.8, 21.7 and 20.3 µM on T24 cells at 24, 48 and 72 h, respectively, indicating that cancer cells have a higher sensitivity towards icaritin than normal human cells, and that icaritin functioned as a promising anticancer agent with low cytotoxicity on normal cells.

Icaritin reduces the capacity of colony formation of bladder cancer cells

To confirm the effect of icaritin on colony-forming ability of bladder cancer cells, cell colony formation assay was performed on BT5637 and T24 cells treated with various concentrations of icaritin for 48 h. As shown in Fig. 2A, the sizes of colony and the numbers of cells/colony in icaritin groups were smaller as compared with the DMSO vehicle control, particularly for BT5637 cells. Moreover, the result showed that the higher concentration of icaritin, the stronger the inhibitory effect. In addition, the number of colonies of BT5637 cells treated with icaritin at the concentrations of 10 and 20 µM was 176.3±8.0 and 95.7±7.1, respectively, and that in T24 cells treated with icaritin at the concentrations of 20 and 50 µM was 250.3±10 and 189.0±16.5, respectively, which was significantly decreased comparing to the DMSO vehicle groups in BT5637 and T24 cells (255.3±13.0 and 305±9.2, respectively) (Fig. 2B). These results suggest that icartin suppressed the capacity of colony formation of bladder cancer cells.

Figure 2 Icaritin inhibits the colony formation of BT5637 and T24 cells. BT5637 and T24 cells (6×102 cells/well) were seeded into 6-well plates and cultured with DMSO vehicle control or different concentrations of icaritin for 48 h. (A) Colony-forming ability was evaluated by colony formation assay. (B and C) The size and number of colonies for BT5637 and T24 cells in different concentrations of icaritin were significantly lower than those in DMSO vehicle control (*P<0.05, **P<0.01, ***P<0.001). Scale bar, 150 µm.

Icaritin reduces mitochondrial membrane potential (MMP) in bladder cancer cells

Mitochondria, known as 'the power house', are important cellular structures that generate adenosine triphosphate (ATP) to supply most cellular functions. They are closely associated with cell cycle progression, cell growth and cell death (28). Therefore, we carried out JC-1 staining assay to evaluate whether icaritin could affect mitochondrial function in BT5637 and T24 cells. The result showed that MMP was reduced in BT5637 and T24 cells treated with icaritin (Fig. 3A). As shown in Fig. 3B and C, the cell viability in BT5637 cells were significantly decreased in 10 and 20 µM icaritin groups as compared with the DMSO vehicle control (94.88±0.06 and 87.77±0.20 vs. 98.35±0.10, P<0.001), and a similar result was seen in T24 cells treated with 20 and 50 µM icaritin (85.34±0.32 and 76.4±10.18 vs. 93.15±0.02, P<0.001), indicating that the cell viability of bladder cancer cells was significantly inhibited after icaritin treatment in a dose-dependent manner.

Figure 3 Icaritin decreases mitochondrial membrane potential (MMP) of BT5637 and T24 cells. BT5637 and T24 cells were incubated with DMSO vehicle control or varying concentrations of icaritin for 72 h. The MMP of cells were evaluated by flow cytometry after labeling of JC-1 staining solution. (A) MMP was significantly decreased in BT5637 and T24 cells treated with icaritin compared with that in DMSO vehicle control. (B) The cell viability of bladder cancer cells in icaritin groups was significantly lower than the control group (***P<0.001).

Icaritin inhibits autophagy of bladder cancer cells

There was no significant change in cell cycle arrest and apoptosis of bladder cancer cells treated with icaritin (data not shown). To verify other potential mechanism of icaritin-induced cell inhibition, we examined the autophagy pathways and postulated that autophagy, which plays a vital role in cleaning injured mitochondria, may act as a major factor in regulating the growth of bladder cancer cells treated with icaritin. Using western blotting, major autophagy proteins including ATG3, ATG5, ATG7, ATG12 and LC3 were investigated to evaluate the autophagy levels of BT5637 and T24 treated with icaritin at 24, 48 and 72 h. Given the lack of the duration of drug action (icaritin treatment for 24 h), both bladder cancer T24 and BT5637 cells showed a slight difference in autophagy or even LC3 was initially upregulated in BT5637 (Fig. 4A). After 48-h treatment, the conversion of LC3-I to LC3-II was reduced (Fig. 4B), indicating that inhibition of autophagy in BT5637 and T24 cells treated with icaritin was initiated. Comparing with the DMSO vehicle control, autophagy of BT5637 and T24 cells significantly decreased in a dose-dependent manner, particularly at 48 and 72 h after 72-h icaritin treatment. The above results suggest that icaritin inhibited the activation of constitutive autophagy.

Figure 4 Icaritin induced autophagy suppression. Both bladder cancer cells T24 and BT5637 were treated with icaritin in 2.5, 5, 10, 20 and 50 µM for 24, 48 and 72 h. Proteins of ATG8 conjugation system including ATG3, ATG5, ATG7 and ATG12 were detected. Additionally, both autophagosome marker LC3-I and LC3-II were discovered.

Incaritin sensitizes bladder cancer cells to EPI by inhibiting EPI-induced autophagy

Knowing that inhibition of autophagy could sensitize cancer cells to chemotherapeutic agents (21,22), we aimed to clarify whether combination of incaritin and EPI for treatment of BT5637 and T24 cells had a synergistic effect on cancer cells. To clarify this, we treated BT5637 and T24 bladder cancer cells with a combination of icaritin and EPI for 24 h and then detected the proliferation of these cells by MTT assay. The results in Fig. 5A and B showed that the IC50 value of icaritin alone (7.07 µM) and EPI alone (4.00 µg/ml) in inhibiting BT5637 cells was significantly higher than that of icaritin in combination with 1.00 µg/ml EPI (0.96 µM) and EPI in combination with 2.5 µM icaritin (1.57 µg/ml). The same interesting results were also observed in T24 cells (Fig. 5C and D). To confirm whether combination of incaritin and EPI had a synergistic effect, we adopted the Chou-Talalay combination index (CI) equation. Based on the calculations, the CI value of icaritin and EPI combination in treating BT5637 and T24 cells was 0.53 and 0.56, respectively (Fig. 5E and F), indicating that icaritin and EPI acted synergistically to suppress the proliferation of bladder cancer cells. To verify our result concerning the synergistic antitumor effect, western blotting was carried out to confirm whether incaritin inhibited EPI-induced autophagy and enhanced the susceptibility of bladder cancer cells to EPI. The result showed that icaritin not only suppressed the production of LC3-I as an autophagic marker in cytoplasm but inhibited the conversion of LC3-I to LC3-II (Fig. 5E and F), suggesting that icaritin could sensitize bladder cancer cells to epirubicin treatment via downregulating EPI-induced autophagy.

Figure 5 Icaritin synergistically potentiates the sensitivity of bladder cancer BT5637 and T24 cells to EPI. A total of 1×104 cells/well BT5637 cells, and 8×103 cells/well T24 cells were seeded into 96-well plates and cultured with icaritin alone, icaritin + EPI (BT5637 cells, 1 µg/ml; T24 cells, 5 µg/ml), EPI alone and EPI + icaritin (BT5637 cells, 2.5 µM; T24 cells, 10 µM) for 24 h. The effects of combination were evaluated by MTT assay. The proliferation of BT5637 and T24 cells undergoing combination therapy was significantly decreased compared with those undergoing either icaritin or EPI treatment alone (A–D). The CI value of BT5637 and T24 cells treated with icaritin + EPI was <1 (E and F), showing a synergic effect. Further investigation on the protein level of autophagy showed that icaritin played a vital role in combination therapy with EPI (G and H).

Discussion

Bladder cancer is notorious for its high recurrence rate. Although a routine intravesical perfusion with EPI after surgery may reduce the recurrence rate, the acquired resistance to EPI is common in cancer patients (29). Therefore, increased attention has been paid to uncover the mechanism of drug resistance, and seeking novel agents among natural herbal ingredients (29).

In the present study, in an effort to find effective compounds to suppress the malignant proliferation of bladder cancer cells, we screen a library of small compound extracted from herbal medicine. We identified that icaritin may inhibit the proliferation of T24 and BT5637 cells. Furthermore, as it has been reported that icariin, an analogue of icaritin, may induce apoptosis in human hepatoma SMMC-7721 cells via a ROS/JNK-dependent mitochondrial pathway (30), we also investigated the effect of icariin on bladder cancer cells. However, differently to that previously reported in hepatoma cells, icariin showed a very low cytotoxicity on bladder cancer cells compared to icaritin. Therefore, icaritin was chosen to further explore the antitumor molecular mechanism in bladder cancer cells. Icaritin significantly inhibited the proliferation and colony formation of bladder cancer cells in a time- and dose-dependent manner. BT5637 cells (IC50 at 24, 48 and 72 h, 11.6, 7.21 and 4.46 µM) showed higher sensitivity to icaritin than T24 cells (IC50 at 24, 48 and 72 h, 36.8, 21.7 and 20.3 µM).

In order to explore the molecular mechanism how icaritin inhibited the proliferation of BT5637 and T24 cells, we analyzed the cell cycle distribution and apoptosis of both cells using PI/Annexin V and flow cytometric analysis. However, the results showed that icaritin hardly affected cell cycle distribution or apoptosis in the cells (data not shown). However, we discovered that mitochondrial membrane potential (MMP) of BT5637 and T24 cells was obviously impaired by icaritin treatment. Mitochondria are known to play a vital role in cell growth as they provide large amounts of ATP for various cellular activities (27). Since tumor cells show extremely active growth, large amounts of ATP are required for tumor cells to support malignant cell proliferation (31). Therefore, decrease of mitochondrial membrane potential may lead to a reduced ATP production and suppressed cell proliferation rate. In the present study, growth inhibitory effect of icaritin in bladder cancer cells may be mediated through MMP suppression.

For eukaryotic cells, autophagy is a crucial pathway to recycle organelles and proteins, especially injured mitochondria. An elevated autophagic activity is utilized by tumor cells to acquire malignant proliferation. The accumulation of injured mitochondria in icaritin-treated bladder cancer cells prompted us to analyze autophagy in these cells. During autophagy, microtubule-associated protein 1A/1B-light chain 3 (LC3) is conjugated to phosphatidylethanolamine to form LC3-phosphatidylethanolamine (LC3-II)-conjugated by two consecutive ubiquitylation-like reactions catalyzed by the E1-like enzyme Atg7 and the E2-like enzyme Atg3 (32,33). LC3-II is recruited to autophagosomal membranes and degraded in autolysosomes after being fused to lysosomes (32,33). Therefore, the protein levels of ATG3, ATG7, LC3 and LC3-II have been demonstrated to be reliable markers to monitor autophagy (32,33). Moreover, ATG12, as the first ubiquitin-like ATG protein to be found, could bind to and was activated by ATG7, an E1-like enzyme (34). The ATG12 is sent to ATG10, an E2 enzyme, and finally forms a conjugation with ATG5, and then the ATG12-ATG5 conjugation futher coacts with ATG16, a small coiled-coil protein, and forms the ATG12-ATG5-ATG6 multimeric complex (34). We found that icaritin downregulated the expressions of ATG3, ATG7, ATG5, ATG12 and suppressed the transformation of LC3 to LC3-II, indicating that icaritin inhibited autophagy of bladder cancer cells.

Previous studies reported that ERK and AKT signaling are the dominant pathway for icaritin to inhibit cancer cells growth in chronic myeloid leukemia, endometrial cancer renal cell carcinoma and breast cancer cells (15,17,18,35). Moreover, Li et al revealed that the apoptosis of human hepatoma was also induced via icariin treatment with ROS/JNK-dependent mitochondrial pathway (30). The above signaling pathways of icaritin were explored in the present study, however, the inhibition of bladder cancer cells undergoing icaritin treatment had no correlation with the signaling (data was not shown). We revealed that icaritin inhibited the autophagy pathway to effective inhibition of bladder cancer cells.

Autophagy is activated in tumor cells compared to normal cells, in response to cellular stress and/or increased metabolic demands, leading to rapid cell proliferation and acquired resistance to chemotherapies (19). Therefore, autophagy which is differentially regulated in cancer and normal cells may serve as a promising target for anticancer therapy. We found that icaritin significantly inhibited the proliferation of bladder cancer cells via downregulated autophagy. However, the IC50 value of icaritin for normal human HEK293 cells at 72 h was 28.4- and 6.2-fold higher than that for BT5637 and T24 cells at 72 h, respectively, suggesting that human bladder cancer BT5637 and T24 cells which have active autophagic activity were more sensitive to icaritin compared to normal human HEK293 cells, and that icaritin may serve as an anticancer agent with low adverse effects.

In clinical practice, intravesical perfusion with epirubicin is routinely used after transurethral resection to prevent bladder cancer recurrence. Nevertheless, there exists an even more serious problem regarding EPI-resistance which limits its successful anticancer effect. In addition, adverse events accompanying high-dose intravesical usage of epirubicin, including chemical cystitis, urinary tract infection, hematuria and cardiac adverse events, have also been shown as a problem for bladder cancer patients (6). Therefore, a combined usage of an agent that can improve the sensitivity of EPI may reduce the side-effects due to high-dose EPI treatment. In the present study, we found that when combined with icaritin, EPI reached the same inhibitory effect on bladder cancer cells at a much lower dose compared to EPI treatment alone, suggesting that icaritin may serve as an adjuvant agent to boost EPI therapy. Recently, Chittaranjan et al found a similar result that EPI-resistant breast cancers cells treated with combination of EPI and autophagy inhibitor (hydroxychloroquine) markedly enhanced the inhibition of tumor growth comparing to those treated with EPI alone (36).

Autophagy is a major way that tumor cells utilize to develop chemoresistances to EPI. It is reported that EPI induces autophagy in human breast cancer MCF-7 cells, and EPI-induced autophagy protects MCF-7 cells from EPI-induced apoptosis (20). Also, EPI induces autophagy and serves as a pro-survival mechanism in triple negative breast cancers (TNBCs) (36). However, it has not been reported whether EPI may cause autophagy in bladder cancer. In the present study, we found that EPI treatment promoted the conversion of LC3I to LC3II, a marker of autophagosome (Fig. 5G and H), implying that EPI may induce autophagy in bladder cancer cells. As identified in Fig. 4 that icaritin acted as an autophagy inhibitor, we tested whether icaritin can suppress autophagy to increase EPI sensitivity in bladder cancer cells. The results showed that EPI-inducing autophagy was suppressed by icaritin treatment. Therefore, we found a novel compound icaritin functioning as an autophagy inhibitor to restore the sensitivity of bladder cancer to EPI.

In conclusion, the present study proposes that icaritin inhibited the malignant proliferation of bladder cancer cells through inhibition of autophagy. Moreover, as an autophagy inhibitor, icaritin functioned synergistically with EPI to treat bladder cancer cells by depressing EPI-induced autophagy. These results provide reasonable evidence that the natural product icaritin may prove to be a novel potent anticancer agent against bladder cancer.

Acknowledgments

The present study was supported by grants from the National Natural Science Foundation of China for Youths (no. 81202020), the National Natural Science Foundation of China (no. 81170637), the Shanghai Committee of Science and Technology General Program for Medicine (no. 11JC1402302), the Military Fund for Health Care (13BJZ29), and the Key Project of Science and Innovation Foundation of Shanghai Ministry of Education (14zz084).

Abbreviations:

References